PRIOR AUTHORIZATION POLICY

POLICY: Oncology – Sprycel Prior Authorization Policy
- Sprycel® (dasatinib tablets – Bristol-Myers Squibb)

REVIEW DATE: 05/01/2024

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Sprycel, a tyrosine kinase inhibitor (TKI), is indicated for the following uses:[1]

- **Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL)**:
  - In adults with resistance or intolerance to prior therapy.
  - In newly diagnosed pediatric patients ≥ 1 year of age in combination with chemotherapy.
- **Ph+ chronic myeloid leukemia (CML)**:
  - Chronic phase in newly diagnosed adults.
  - Chronic phase, accelerated, or myeloid or lymphoid blast phase, in adults with resistance or intolerance to prior therapy including imatinib.
  - Chronic phase, in pediatric patients ≥ 1 year of age.

Guidelines

Sprycel is addressed in guidelines from National Comprehensive Cancer Network (NCCN):

- **ALL:** NCCN guidelines for adults and adolescents (version 4.2023 – February 5, 2024) recommend Sprycel for Ph+ disease in many different clinical circumstances (e.g., induction, consolidation therapy, maintenance, or relapsed or refractory disease) [category 2A].[2] TKIs in combination with other

agents (e.g., chemotherapy or corticosteroids) are recommended for induction therapy for Ph+ ALL. TKIs have also been incorporated into consolidation and maintenance therapy, as well as in the relapsed/refractory setting (category 2A). TKI options include: Bosulif® (bosutinib tablets), Sprycel, imatinib, Tasigna (nilotinib capsules), or Iclusig® (ponatinib tablets) [category 2A]. NCCN panel notes that not all TKIs have been directly studied within the context of each specific regimen and there are limited data for Bosulif in Ph+ ALL. Use of a specific TKI should account for anticipated/prior TKI intolerance and disease-related features. For adults and adolescents, Iclusig has activity against T315I mutations and/or in whom no other TKI is indicated (category 2A). NCCN guidelines for pediatric ALL (version 5.2024 – April 3, 2024) feature Sprycel prominently in a variety of clinical scenarios (mainly category 2A recommendations).[3]

- **Bone Cancer:** NCCN guidelines (version 2.2024 – March 12, 2024) recommend Sprycel for patients with chondrosarcoma as "other recommended regimens" for a patient with metastatic and widespread disease (category 2A).[4] Sprycel is also recommended for recurrent conventional or chondroid chordoma as "other recommended regimens" (category 2A).
- **CML:** NCCN guidelines (version 2.2024 – December 5, 2023) recommend Sprycel as a "preferred" primary treatment for newly diagnosed chronic phase Ph+ CML with a low-, intermediate-, or high-risk score (category 1).[5] Sprycel is also recommended as an alternative TKI treatment (after primary treatment with imatinib, Bosulif® [bosutinib tablets], or Tasigna® [nilotinib capsules]) (category 2A). Sprycel is also recommended in a variety of other situations, including post-allogeneic hematopoietic stem cell transplant (category 2A).
- **Gastrointestinal Stromal Tumor:** NCCN guidelines (version 1.2024 – March 8, 2024) recommend Sprycel as a second-line therapy as "other recommended regimens" for unresectable, progressive or metastatic disease in patients with platelet-derived growth factor receptor alpha *[PDGFRA]* exon 18 mutations that are insensitive to imatinib (including the *PDGFRA* D842V mutation) [category 2A].[6]
- **Melanoma: Cutaneous**: NCCN guidelines (version 2.2024 – April 3, 2024) recommend Sprycel as "useful in certain circumstances" for metastatic or unresectable disease with an activating *KIT* mutation as second-line or subsequent therapy for disease progression, intolerance, and/or projected risk of progression with *BRAF*-targeted therapy (category 2A).[7]
- **Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions:** NCCN guidelines (version 1.2024 – December 21, 2023) list Sprycel as a "preferred" therapy for chronic phase or blast phase disease with an *ABL1* rearrangement (category 2A).[8,9]. It is also recommended as treatment in combination with ALL- or acute myeloid leukemia-type induction chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HCT) (if eligible) for lymphoid, myeloid or mixed lineage neoplasms with eosinophilia and *ABL1* rearrangement in blast phase (category 2A).[9]

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Sprycel. All approvals are provided for the duration noted below.

- **Sprycel® (dasatinib tablets (Bristol-Myers Squibb)**

is(are) covered as medically necessary when the following criteria is(are) met for fda-approved indication(s) or other uses with supportive evidence (if applicable):

FDA-Approved Indications

1. **Acute Lymphoblastic Leukemia.** Approve for 1 year if the patient has Philadelphia chromosome-positive acute lymphoblastic leukemia.

2. **Chronic Myeloid Leukemia.** Approve for 1 year if the patient has Philadelphia chromosome-positive chronic myeloid leukemia.

Other Uses with Supportive Evidence

3. **Bone Cancer.** Approve for 1 year if the patient meets BOTH of the following (A and B):
   A) Patient is ≥ 18 years of age; AND
   B) Patient has chondrosarcoma or chordoma.

4. **Gastrointestinal Stromal Tumor.** Approve for 1 year if the patient meets BOTH of the following (A and B):
   A) Patient is ≥ 18 years of age; AND
   B) Patient has tried imatinib or Ayvakit (avapritinib tablets).

5. **Melanoma, Cutaneous.** Approve for 1 year if the patient meets ALL of the following (A, B, C, and D):
   A) Patient is ≥ 18 years of age; AND
   B) Patient has metastatic or unresectable disease; AND
   C) Patient has an activating *KIT* mutation; AND
   D) Patient has tried at least one systemic regimen.
   Note: Examples of a systemic regimen include: Opdivo (nivolumab intravenous infusion) + Yervoy (ipilimumab intravenous infusion), Opdivo + Opdualag (nivolumab/relatlimab-rmbw intravenous infusion), Keytruda (pembrolizumab intravenous infusion), Opdivo, Tafinlar (dabrafenib capsules and oral tablets for suspension) + Mekinist (trametinib tablets), Zelboraf (vemurafenib tablets) + Cotellic (cobimetinib tablets), Braftovi (encorafenib capsules) + Mektovi (binimetinib tablets).

6. **Myeloid/Lymphoid Neoplasms with Eosinophilia.** Approve for 1 year if the patient meets BOTH of the following (A and B):
   A) Patient is ≥ 18 years of age; AND
   B) The tumor has an *ABL1* rearrangement.

CONDITIONS NOT COVERED

**Sprycel® (dasatinib tablets (Bristol-Myers Squibb)
is(are) considered experimental, investigational or unproven for ANY other use(s)**

REFERENCES

1. Sprycel® tablets [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; February 2023.
2. The NCCN Acute Lymphoblastic Leukemia Clinical Practice Guidelines in Oncology (version 4.2023 – February 5, 2024). © 2024 National Comprehensive Cancer Network. Available at: http://www.nccn.org. Accessed on April 29, 2024.
3. The NCCN Pediatric Acute Lymphoblastic Leukemia Clinical Practice Guidelines in Oncology (version 5.2024 – April 3, 2024). © 2024 National Comprehensive Cancer Network. Available at: http://www.nccn.org. Accessed on April 29, 2024.
4. The NCCN Bone Cancer Clinical Practice Guidelines in Oncology (version 2.2024 – March 12, 2024). © 2024 National Comprehensive Cancer Network. Available at: http://www.nccn.org. Accessed on April 29, 2024.
5. The NCCN Chronic Myeloid Leukemia Clinical Practice Guidelines in Oncology (version 2.2024 – December 5, 2023). © 2023 National Comprehensive Cancer Network. Available at: http://www.nccn.org. Accessed on April 29, 2024.
6. The NCCN Gastrointestinal Stromal Tumors Guidelines in Oncology (version 1.2024 – March 8, 2024). © 2024 National Comprehensive Cancer Network. Available at: http://www.nccn.org. Accessed on April 29, 2024.
7. The NCCN Melanoma: Cutaneous Clinical Practice Guidelines in Oncology (version 2.2024 – April 3, 2024). © 2024 National Comprehensive Cancer Network. Available at: http://www.nccn.org. Accessed on April 29, 2024.
8. The NCCN Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Clinical Practice Guidelines in Oncology (version 1.2024 – December 21, 2023). © 2023 National Comprehensive Cancer Network. Available at: http://www.nccn.org. Accessed on April 29, 2024.
9. The NCCN Drugs and Biologics Compendium. © 2024 National Comprehensive Cancer Network. Available at: http://www.nccn.org. Search term: dasatinib. Accessed on April 29, 2024.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	**Bone Cancer**: The condition of approval of chondrosarcoma or chordoma was reworded to bone cancer and criterion was added which states that patient has chondrosarcoma or chordoma. **Melanoma, Cutaneous:** This new condition of approval was added to "Other Uses With Supportive Evidence" section based on NCCN guideline recommendations.	05/31/2023
Annual Revision	No criteria changes.	05/01/2024